Moderate
Probable
Description
Carbamazepine substantially reduces duloxetine plasma levels through CYP1A2 and CYP3A4 induction, risking loss of antidepressant efficacy.
Mécanisme
Carbamazepine induces CYP1A2 and CYP3A4, the primary enzymes responsible for duloxetine oxidative metabolism, significantly increasing its clearance.
Signification clinique
Duloxetine concentrations may drop well below effective levels; depression or pain relapse is a realistic clinical outcome.
Prise en charge
Closely monitor clinical response; consider antidepressants less susceptible to enzyme induction (e.g., venlafaxine) if carbamazepine is required.